Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures

被引：40
作者：
Huang, Xuan
Chau, Cindy H. [1 ]
Figg, William D. [1 ]
机构：
[1] NCI, Mol Pharmacol Sect, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷
基金：
美国国家卫生研究院;
关键词：
CIRCULATING TUMOR-CELLS; PHASE-II TRIAL; ABIRATERONE ACETATE; CLINICAL-TRIALS; END-POINTS; ANTITUMOR-ACTIVITY; PLUS PREDNISONE; POST-DOCETAXEL; DOUBLE-BLIND; SURVIVAL;
D O I：
10.1186/1756-8722-5-35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic agents has been made in the past few years. While sipuleucel-T, cabazitaxel, and abiraterone gained regulatory approval in 2010 and 2011, several highly promising candidates/regimens have failed in large scale clinical trials. Challenges remain to optimize the design and interpretation of clinical trial results and develop more effective strategies for mCRPC. In this review, we examined the positive and negative clinical trials in mCRPC in the past and discussed the various aspects of clinical trial design including selection of targets and appropriate outcome measures, biomarker development and implementation, and strategies for combination therapy.
引用
收藏
页数：8
相关论文
共 62 条
[41]   Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space [J].
Sartor, A. Oliver .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
[42]  
Sartor AOHD, 2012, J CONTRACEPT FERTIL, V30
[43]   Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis [J].
Scher, HI ;
Sawyers, CL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (32) :8253-8261
[44]   Prostate cancer clinical trial end points: "RECIST"ing a step backwards [J].
Scher, HI ;
Morris, MJ ;
Kelly, WK ;
Schwartz, LH ;
Heller, G .
CLINICAL CANCER RESEARCH, 2005, 11 (14) :5223-5232
[45]  
Scher HIFK, 2012, J CONTRACEPT FERTIL, V30, pLBA1
[46]   Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group [J].
Scher, Howard I. ;
Halabi, Susan ;
Tannock, Ian ;
Morris, Michael ;
Sternberg, Cora N. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Higano, Celestia ;
Bubley, Glenn J. ;
Dreicer, Robert ;
Petrylak, Daniel ;
Kantoff, Philip ;
Basch, Ethan ;
Kelly, William Kevin ;
Figg, William D. ;
Small, Eric J. ;
Beer, Tomasz M. ;
Wilding, George ;
Martin, Alison ;
Hussain, Maha .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1148-1159
[47]   The association between measures of progression and survival in castrate-metastatic prostate cancer [J].
Scher, Howard I. ;
Warren, Mary ;
Heller, Glenn .
CLINICAL CANCER RESEARCH, 2007, 13 (05) :1488-1492
[48]   Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study [J].
Scher, Howard I. ;
Beer, Tomasz M. ;
Higano, Celestia S. ;
Anand, Aseem ;
Taplin, Mary-Ellen ;
Efstathiou, Eleni ;
Rathkopf, Dana ;
Shelkey, Julia ;
Yu, Evan Y. ;
Alumkal, Joshi ;
Hung, David ;
Hirmand, Mohammad ;
Seely, Lynn ;
Morris, Michael J. ;
Danila, Daniel C. ;
Humm, John ;
Larson, Steve ;
Fleisher, Martin ;
Sawyers, Charles L. .
LANCET, 2010, 375 (9724) :1437-1446
[49]   Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data [J].
Scher, Howard I. ;
Jia, Xiaoyu ;
de Bono, Johann S. ;
Fleisher, Martin ;
Pienta, Kenneth J. ;
Raghavan, Derek ;
Heller, Glenn .
LANCET ONCOLOGY, 2009, 10 (03) :233-239
[50]   The genetics of castration-resistant prostate cancer: What can the germline tell us? [J].
Sharifi, Nima ;
Dahut, William L. ;
Figg, William D. .
CLINICAL CANCER RESEARCH, 2008, 14 (15) :4691-4693
1234567